Oxford BioMedica and Orchard ink gene therapy deal

Strategic alliance combines gene and cell therapy approaches for rare immune diseases.

By Suzanne Elvidge • Nov. 30, 2016

MedImmune, Abpro link up to accelerate antibody development

The deal adds to what has been a hectic few months of M&A for AstraZeneca, MedImmune's parent company. 

By Jacob Bell • Nov. 29, 2016

Idera sells licensing rights to shelved autoimmune drug

The deal gives Idera, which has been hungry for cash to push candidates through clinical trials, $15 million upfront. 

By Jacob Bell • Nov. 28, 2016

J&J gives nod to Actelion rumors

Companies confirmed talks for a deal that could be worth more than $20 billion.

By Suzanne Elvidge • Nov. 28, 2016

Allergan builds Alzheimer's portfolio with Chase acquisition

The deal came just hours before Eli Lilly announced its highly anticipated Alzheimer's treatment failed in Phase 3. 

By Jacob Bell • Nov. 23, 2016

Quintiles IMS hooks up with big pharma on data deal

Collaboration with the pharma industry will give QuintilesIMS access to real-world cancer data.

By Suzanne Elvidge • Nov. 23, 2016

Walgreens expands partnership providing patient drug reviews

The deal will provide more detailed product reviews from online forum PatientLikeMe's more than 400,000 users.

By Jacob Bell • Nov. 22, 2016

Novartis snags sickle cell drug in Selexys acquisition

The deal, worth up to $665 million, further solidifies the Swiss pharma's footing in the hematology drug space.

By Jacob Bell • Nov. 21, 2016

Prescribed Reading: Data, arrests, pricing batter pharma

Gilead falters, ex-Valeant exec indicted, combo data dominates in hep C and pricing worries continue. 

By Lisa LaMotta • Nov. 18, 2016

GlobeImmune CEO steps down as partnership with Gilead fizzles

The announcements continue a string of bad news that has plagued the clinical-stage biopharma for more than a year.

By Jacob Bell • Nov. 18, 2016

Grunenthal buys Pittsburgh firm to expand pain-fighting portfolio

Thar Pharmaceuticals abandons IPO plans in favor of deal with German giant.

By Judy Packer-Tursman • Nov. 18, 2016

Eagle acquires Arsia, moves in on biosimilars

The target company's technology platform will allow Eagle to soar above other biosimilar developers.

By Jacob Bell • Nov. 17, 2016

Bristol continues microbiome exploration with Enterome deal

The agreement follows Bristol's decision earlier this month to partner with Johns Hopkins University on research into the hot field. 

By Jacob Bell • Nov. 16, 2016

Prescribed Reading: Trump wasn't the only news in pharma

Bristol-Myers made portfolio changes, Europe welcomed several biosimilars to market, the FDA talked off-label promotion and multiple drugs were hit with holds. 

By Lisa LaMotta • Nov. 11, 2016

Bristol digs deeper into NASH with Nitto deal

Like other pharmas, Bristol-Myers sees potential in the unmet need for treatments of the fatty liver disease. 

By Jacob Bell • Nov. 10, 2016

Orexigen and Valeant bulk up Contrave deal

The two floundering companies expanded a marketing partnership into new territories. 

By Lisa LaMotta • Nov. 9, 2016

Takeda adds digital health tools in Koneksa deal

The Japanese drugmaker hopes to use biosensor and wearable tech in a number of early-stage clinical trials. 

By Suzanne Elvidge • Nov. 9, 2016

Gilead on the 'hunt for better assets'

One analyst suggests the big biotech, "still on the prowl," might have an eye on Alexion Pharmaceuticals. 

By Judy Packer-Tursman • Nov. 8, 2016

Lexicon buys Bristol neuro drug

The deal stands to further refine Bristol-Myers's pipeline, a trend that has rippled across pharma for much of 2016.

By Jacob Bell • Nov. 8, 2016

Medivir rounds out oncology portfolio with new deal

The Swedish pharma switched gears recently and is bolstering its position in cancer by adding two clinical-stage drugs. 

By Suzanne Elvidge • Nov. 7, 2016

Nestlé invests $145M in food allergy company

Nestlé Health Science's investment could speed development of Aimmune's immunotherapy for peanut allergy.

By Suzanne Elvidge • Nov. 7, 2016

Prescribed Reading: ASH abstracts hit biotech hard

Companies refocus their M&A strategies, while abstracts from the upcoming ASH meeting disappoint investors and new discoveries could help treat a rare disease. 

By Lisa LaMotta • Nov. 4, 2016

EnBiotix gets the bug for AMPT antimicrobials

The bioengineering company has acquired German AMP Therapeutics and its portfolio of anti-microbial peptides. 

By Suzanne Elvidge • Nov. 4, 2016

Troubled Infinity licenses cancer drug to Verastem

The Cambridge-based biotech is attempting to adjust after a terminated partnership with AbbVie and lackluster trial results buried the company's stock. 

By Jacob Bell • Nov. 3, 2016

Ergomed, Asarina partner on treatment for severe premenstrual syndrome

Sepranolone is the first product being developed exclusively for the often-debilitating condition.

By Judy Packer-Tursman • Nov. 3, 2016